Search all medical codes

Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions

CPT4 code

Name of the Procedure:

Infectious Agent Genotype Analysis by Nucleic Acid (DNA or RNA); HIV-1, Reverse Transcriptase and Protease Regions

Summary

This procedure tests for specific genetic variations in the HIV-1 virus. It examines two key regions of the virus, the reverse transcriptase, and protease regions, to understand how the virus may respond to different treatments.

Purpose

  • Addresses the medical condition of HIV-1 infection.
  • Helps determine the most effective antiretroviral therapy by identifying resistance mutations in the HIV-1 virus.

Indications

  • HIV-positive patients with a high viral load.
  • Patients experiencing failure in current antiretroviral therapy.
  • People newly diagnosed with HIV to guide initial treatment.

Preparation

  • No special preparations or fasting required.
  • Blood sample is typically required.
  • Inform the healthcare provider of any current medications.

Procedure Description

  1. Blood samples are collected from the patient.
  2. The sample is processed in a laboratory to extract DNA or RNA.
  3. Specific regions of the HIV-1 genome (reverse transcriptase and protease regions) are amplified and sequenced.
  4. The genetic sequences are analyzed to detect mutations that may confer drug resistance.
    • Equipment includes PCR machines and sequencing technology.
    • No anesthesia or sedation is necessary.

Duration

Typically, it takes a few hours to a few days for the analysis to be completed in the lab.

Setting

Performed in a specialized laboratory equipped for genetic analysis.

Personnel

  • Phlebotomist or nurse to draw blood.
  • Laboratory technicians or molecular biologists to process and analyze the samples.

Risks and Complications

  • Minor discomfort or bruising at the blood draw site.
  • Rare risk of infection at the puncture site.
  • Laboratory errors, though infrequent, can lead to inaccurate results.

Benefits

  • Personalized HIV treatment plans optimized for better outcomes.
  • Improved management of HIV medication, reducing the risk of resistance.
  • Quick turnaround allows timely decisions on therapy adjustments.

Recovery

  • No recovery time needed for the blood draw.
  • Patients can resume normal activities immediately after the sample collection.
  • Follow-up involves discussing test results with the healthcare provider for further treatment planning.

Alternatives

  • Phenotypic resistance testing: assesses the growth of the virus in response to medications.
  • Integrated therapy without prior genotype testing, though less precise.
  • Pros and cons: Genotypic testing is faster and more specific, but phenotypic testing may be more comprehensive.

Patient Experience

  • The patient might feel a small pinch during the blood draw.
  • Little to no discomfort after the blood draw.
  • Emotional relief from receiving precise treatment recommendations.

Similar Codes